Investors in Symrise AG are facing a confluence of strategic and market developments as the company approaches a pivotal reporting date. The upcoming release of the Corporate Report 2025 this Wednesday is set to provide concrete financial context to recent signals, including an accelerated share buyback and a notable shift in short-selling activity.
The stock closed yesterday’s session at 76.72 euros. Despite recent movements, it remains down 20.38% over a 12-month period, underscoring a market that is looking for substantive progress rather than mere positive sentiment.
Share Buyback Program Gains Momentum
Symrise’s ongoing share repurchase initiative continues at a significant pace. During the week of 16 to 20 February, the company acquired 156,000 of its own shares. The weekly volume amounted to approximately 11.7 million euros, with a weighted average price of 75.09 euros per share.
Since the program’s commencement on 2 February 2026, total buybacks have reached 471,143 shares (as of 20 February). Announced on 12 January, this program has a total volume of up to 400 million euros and is scheduled to run until 31 October 2026. Its stated purpose is the cancellation of the repurchased shares, leading to a reduction in share capital. A mandated credit institution is executing the purchases across several trading venues.
Short Interest Plummets in US Markets
In a parallel development, the Short Interest for Symrise’s American Depositary Receipts (SYIEY) on US over-the-counter markets has seen a dramatic decline. As of the reporting date of 13 February, reported short sales stood at 40,582 shares—a sharp drop from the 187,110 shares reported on 29 January. This represents a decrease of 78.3%.
Should investors sell immediately? Or is it worth buying Symrise?
This shift indicates a notable change in market positioning. Traders who had previously bet on a declining share price have substantially scaled back those positions. Whether this move is primarily a risk reduction tactic ahead of the earnings release or signals a more fundamental reassessment of the stock may become clearer with the Corporate Report 2025, scheduled for 4 March at 7:30 AM CET.
Key Focus Areas for the 2025 Report
The imminent report will deliver the complete financial figures for 2025, revealing whether the company has met its previously communicated targets. In its 2025 half-year report, Symrise raised its EBITDA margin forecast from approximately 21% to around 21.5%. The company also projected organic sales growth of 5 to 7%.
The broader strategic context adds further weight to this report. In January 2026, Symrise decided to divest its terpene business and recorded a non-cash impairment on its investment in Swedencare AB. Management stated these measures are intended to enhance financial flexibility under its ONE-Symrise strategy. Additionally, the company received favorable news as the US Department of Justice closed its antitrust investigation; a letter dated 5 February confirmed no unlawful practices were identified.
Consequently, 4 March serves as a critical litmus test. The report will determine if the aggressive share buyback, recent portfolio actions, and the easing of short-selling pressure are justified by the actual results and target achievements for 2025. The next scheduled milestone follows shortly after, with the Q1 2026 quarterly statement due on 29 April 2026.
Ad
Symrise Stock: Buy or Sell?! New Symrise Analysis from April 14 delivers the answer:
The latest Symrise figures speak for themselves: Urgent action needed for Symrise investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 14.
Symrise: Buy or sell? Read more here...
